Suppr超能文献

[肿瘤血管生成作为腋窝淋巴结阴性乳腺癌独立预后因素的意义]

[Significance of tumor angiogenesis as an independent prognostic factor in axillary node-negative breast cancer].

作者信息

Inada K, Toi M, Hoshina S, Hayashi K, Tominaga T

机构信息

Dept. of Surgery, Tokyo Metropolitan Komagome Hospital.

出版信息

Gan To Kagaku Ryoho. 1995 Apr;22 Suppl 1:59-65.

PMID:7538284
Abstract

The value of tumor angiogenesis, EGFR and c-erbB-2 oncoprotein, a long with p 53 protein expression for predicting relapse-free survival was investigated in 110 node-negative breast cancer patients. The grade of neovascularization was assessed by the microvessel density which was obtained by an immunocytochemical staining by factor VIII-related antigen. EGFR, c-erbB-2 oncoprotein and p 53 oncoprotein were also determined by immunocytochemical assay. Univariate analysis showed no statistical significance of EGFR, c-erbB-2 and p53 status as a prognostic indicator. However, the microvessel density was a significant predictor of relapse-free survival. Patients with over 100 counts of factor VIII-RA positive cells per mm2 field in the most active areas of neovascularization showed significantly poorer prognosis compared to those with less than 100 counts (p < 0.005). Multivariate analysis demonstrated that microvessel density was an independent prognostic indicator in node-negative breast cancer patients (p < 0.0005). It was suggested that microvessel density might be of use in selecting the high-risk group in node-negative breast cancer patients needing adjuvant therapies.

摘要

在110例淋巴结阴性乳腺癌患者中,研究了肿瘤血管生成、表皮生长因子受体(EGFR)和c-erbB-2癌蛋白以及p53蛋白表达对预测无复发生存的价值。通过免疫细胞化学染色因子VIII相关抗原获得微血管密度来评估新生血管形成的程度。EGFR、c-erbB-2癌蛋白和p53癌蛋白也通过免疫细胞化学分析来测定。单因素分析显示,EGFR、c-erbB-2和p53状态作为预后指标无统计学意义。然而,微血管密度是无复发生存的显著预测指标。在新生血管形成最活跃区域每平方毫米视野中因子VIII-RA阳性细胞计数超过100个的患者,与计数少于100个的患者相比,预后明显较差(p<0.005)。多因素分析表明,微血管密度是淋巴结阴性乳腺癌患者的独立预后指标(p<0.0005)。提示微血管密度可能有助于筛选需要辅助治疗的淋巴结阴性乳腺癌高危患者群体。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验